Clinical trial

Reverse Triple Negative Immune Resistant Breast Cancer

NCT05076682

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-06-30

PhasePHASE2

Study timeline

Study start (actual)2022-06-30Date precision: day

Registry last updated2025-12-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple-negative Breast Cancerunresolved

Interventions

CholineDRUG · verified · RxNorm: choline

anti-PD-1 antibody and chemotherapyDRUG

Sodium CromoglicateDRUG

EfavirenzDRUG · verified · RxNorm: efavirenz

MecapegfilgrastimDRUG

TheophyllineDRUG · verified · RxNorm: theophylline

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05076682 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.